These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
360 related items for PubMed ID: 20302159
41. New strategies in the management of inflammatory bowel disease. Rutgeerts P, Baert F. Acta Clin Belg; 1999 Oct; 54(5):274-80. PubMed ID: 10555385 [Abstract] [Full Text] [Related]
42. [Medical therapy of inflammatory bowel diseases: Crohn's disease]. Lakatos L, Lakatos PL. Orv Hetil; 2007 Jun 17; 148(24):1107-14. PubMed ID: 17561480 [Abstract] [Full Text] [Related]
43. Maintenance drugs for inflammatory bowel disease. Drug Ther Bull; 2001 Dec 17; 39(12):91-5. PubMed ID: 11799594 [Abstract] [Full Text] [Related]
44. [Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy]. Ochsenkühn T, Sackmann M, Göke B. Radiologe; 2003 Jan 17; 43(1):1-8. PubMed ID: 12552369 [Abstract] [Full Text] [Related]
46. [Treatment of steroid-refractory ulcerative colitis with infliximab]. Castro Fernández M, García Díaz E, Romero M, Galán Jurado V, Rodríguez Alonso C. Gastroenterol Hepatol; 2003 Jan 17; 26(1):54-5. PubMed ID: 12525332 [No Abstract] [Full Text] [Related]
47. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient]. Hellström PM, Schmidt D, Karlén P. Lakartidningen; 2003 Jan 17; 104(41):2973-6. PubMed ID: 17977308 [No Abstract] [Full Text] [Related]
53. Leukocytapheresis in patients with moderate-severe steroid-dependant ulcerative colitis: clinical response without endoscopic response. Modesto I, Scimeca D, Orlando A, Cottone M. Inflamm Bowel Dis; 2006 Oct 20; 12(10):1009-10. PubMed ID: 17012976 [No Abstract] [Full Text] [Related]
54. [CED therapy with infliximab. Rapid and lasting remission - complete mucosal healing]. Wedekind S. MMW Fortschr Med; 2011 Dec 01; 153(48):54-5. PubMed ID: 22299262 [No Abstract] [Full Text] [Related]
55. Treatment of Crohn's disease at the turn of the century. Bickston SJ, Cominelli F. N Engl J Med; 1998 Aug 06; 339(6):401-2. PubMed ID: 9691110 [No Abstract] [Full Text] [Related]
56. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Schröder O, Blumenstein I, Schulte-Bockholt A, Stein J. Aliment Pharmacol Ther; 2004 Feb 01; 19(3):295-301. PubMed ID: 14984376 [Abstract] [Full Text] [Related]
57. Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience. Maconi G, Mezzina N, Landi S, Grillo S, Bezzio C, Bosani M, Pastorelli L, Dell'Era A, Chibbar R, Carmagnola S, Molteni P, Cassinotti A, Massari A, Ardizzone S. United European Gastroenterol J; 2019 Nov 01; 7(9):1164-1170. PubMed ID: 31700629 [Abstract] [Full Text] [Related]
58. [News from the Cochrane Library: Maintenance of remission in ulcerative colitis]. Timmer A. Z Gastroenterol; 2007 May 01; 45(5):395-6. PubMed ID: 17503319 [No Abstract] [Full Text] [Related]
59. Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease. Rutgeerts P. Gut; 1999 Jul 01; 45(1):13-4. PubMed ID: 10498451 [No Abstract] [Full Text] [Related]